196 related articles for article (PubMed ID: 34889389)
1. Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?
Luskin MR
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):7-14. PubMed ID: 34889389
[TBL] [Abstract][Full Text] [Related]
2. SOHO State of the Art Updates and Next Questions | Approach to Older Adults With Phildadelphia-Chromosome Negative Acute Lymphoblastic Leukemia.
Shimony S; Luskin MR
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):133-140. PubMed ID: 38102012
[TBL] [Abstract][Full Text] [Related]
3. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Jabbour EJ; Sasaki K; Ravandi F; Short NJ; Garcia-Manero G; Daver N; Kadia T; Konopleva M; Jain N; Cortes J; Issa GC; Jacob J; Kwari M; Thompson P; Garris R; Pemmaraju N; Yilmaz M; O'Brien SM; Kantarjian HM
Cancer; 2019 Aug; 125(15):2579-2586. PubMed ID: 30985931
[TBL] [Abstract][Full Text] [Related]
4. Management of acute lymphoblastic leukemia in older adults.
Jammal N; Kantarjian HM; Haddad F; Jabbour EJ
Clin Adv Hematol Oncol; 2022 Mar; 20(3):161-168. PubMed ID: 36607346
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.
Liu D; Zhao J; Song Y; Luo X; Yang T
J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842
[TBL] [Abstract][Full Text] [Related]
6. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
Samra B; Jabbour E; Ravandi F; Kantarjian H; Short NJ
J Hematol Oncol; 2020 Jun; 13(1):70. PubMed ID: 32503572
[TBL] [Abstract][Full Text] [Related]
7. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
8. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
9. Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia.
Short NJ; Kantarjian H; Jabbour E; Ravandi F
Curr Hematol Malig Rep; 2018 Apr; 13(2):91-99. PubMed ID: 29423571
[TBL] [Abstract][Full Text] [Related]
10. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
[TBL] [Abstract][Full Text] [Related]
11. Antibody based therapy in relapsed acute lymphoblastic leukemia.
Jammal N; Chew S; Jabbour E; Kantarjian H
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101225. PubMed ID: 33279181
[TBL] [Abstract][Full Text] [Related]
12. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
[TBL] [Abstract][Full Text] [Related]
13. Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Song J; Ma Q; Gao W; Cong Z; Xie J; Zimmerman Z; Belton L; Franklin J; Palmer S
Adv Ther; 2019 Apr; 36(4):950-961. PubMed ID: 30758745
[TBL] [Abstract][Full Text] [Related]
14. SOHO State of the Art Updates and Next Questions: Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future.
Luskin MR
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):436-441. PubMed ID: 34996739
[TBL] [Abstract][Full Text] [Related]
15. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
[TBL] [Abstract][Full Text] [Related]
16. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment patterns of novel drugs in relapsed or refractory acute lymphoblastic leukemia patients in Japan.
Moribe T; Xu L; Tajima K; Yonemoto N
Future Oncol; 2023 Jun; 19(19):1343-1356. PubMed ID: 37212792
[TBL] [Abstract][Full Text] [Related]
18. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
19. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
Wullenkord R; Reicherts C; Mikesch JH; Marx J; Wethmar K; Albring J; Call S; Lenz G; Stelljes M
Ann Hematol; 2021 Feb; 100(2):587-589. PubMed ID: 32829460
[No Abstract] [Full Text] [Related]
20. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Pullarkat VA; Lacayo NJ; Jabbour E; Rubnitz JE; Bajel A; Laetsch TW; Leonard J; Colace SI; Khaw SL; Fleming SA; Mattison RJ; Norris R; Opferman JT; Roberts KG; Zhao Y; Qu C; Badawi M; Schmidt M; Tong B; Pesko JC; Sun Y; Ross JA; Vishwamitra D; Rosenwinkel L; Kim SY; Jacobson A; Mullighan CG; Alexander TB; Stock W
Cancer Discov; 2021 Jun; 11(6):1440-1453. PubMed ID: 33593877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
